Abstract：Objective: To analyze the effect of Banxia Xiexin Decoction combined with Jinghua Weikang capsule on CA724 and PG1 levels in patients with chronic atrophic gastritis. Methods: A total of 100 patients with chronic atrophic gastritis admitted to our hospital from October 2019 to October 2021 were selected as the research objects, and they were divided into control group and research group, 50 cases in each. Control group was given Jinghua Weikang capsule, study group was given Banxia Xiexin Decoction combined with Jinghua Weikang capsule. The levels of CA724, PG1, inflammatory factors and gastric mucosa function related indicators in the two groups were detected, and the TCM symptom scores, adverse reactions and clinical efficacy were compared between the two groups. Results: Comparison of dry mouth and bitter taste, epigastric fullness, epigastric fullness, nausea and vomiting, CA724, PG1, IL-6, IL-1β, TNF-α, PGE2, GSH-px between the two groups before and after treatment. Dry mouth, stomach fullness, epigastric fullness, nausea and vomiting scores, CA724, IL-6, IL-1β, TNF-α levels decreased more than the control group, and PG1, PGE2, GSH-px levels increased more than the control group group (P<0.05). The adverse effects were slightly higher than the control group (P>0.05), and the treatment response rate was higher than the control group (P<0.05). Conclusion: After combined treatment with Banxia Xiexin Decoction and Jinghua Weikang Capsules, the levels of CA724 and inflammatory factors in patients with chronic atrophic gastritis decreased, the level of PG1 increased, and the gastric mucosal function improved.
[1] Ji Q,Yang Y,Song X,et al.Banxia Xiexin Decoction in the treatment of chronic atrophic gastritis:a protocol for systematic review and meta- analysis[J].Medicine(Baltimore),2020,99(42):22110. [2] Wang YK,Shen L,Yun T,et al.Histopathological classification and follow-up analysis of chronic atrophic gastritis[J].World Clin Cases,2021,9(16):3838-3847. [3] Yue P,Zhong J,Huang J,et al.The efficacy and safety of Xiangsha Liujunzi decoction in the treatment of chronic non-atrophic gastritis:a protocol for a systematic review and meta-analysis[J].Medicine(Baltimore),2021,100(4):e24504. [4] 瞿先侯,杨洋,苏晓兰,等.半夏泻心汤为基础方辨治慢性萎缩性胃炎伴癌前病变的经验[J].环球中医药,2019,12(2):263-265. [5] 中国中西医结合学会消化系统疾病专业委员会.慢性胃炎中西医结合诊疗共识意见[J].中国中西医结合杂志,2012,32(6):738-743. [6] 罗长琴,肖翔,申光富.慢性萎缩性胃炎伴Hp感染患者血清GH、PGⅠ/PGⅡ、TGF-βRⅡ、IL-6和TNF-α水平的变化及临床意义[J].海南医学,2021,32(18):2334-2337. [7] 刘伟锋,黄菊芳,蒋玉萍.健脾益胃方治疗慢性萎缩性胃炎的临床疗效及对胃蛋白酶原的影响[J].广西医学,2021,43(7):815-818. [8] 王瑞昕,张声生,周强.荆花胃康胶丸联合标准四联疗法对Hp相关性慢性胃炎患者的疗效研究[J].中国中西医结合消化杂志,2021,29(9):610-614. [9] 刘冠岐,曾玲玲,丁婷婷,等.柴胡疏肝散联合半夏泻心汤治疗慢性萎缩性胃炎的疗效[J].中国临床研究,2021,34(11):1540-1543. [10] 刘明峰,陈妍.柴芍六君子汤联合西药对慢性萎缩性胃炎患者胃泌素-17、胃蛋白酶原及糖类抗原724的影响[J].现代中西医结合杂志,2020,29(9):987-991. [11] 马耿,张丽贤.标准四联疗法对幽门螺杆菌阳性慢性萎缩性胃炎患者血清GH、PGⅠ、PGⅡ、IL、TGF-β1水平及预后的影响分析[J].中国医学前沿杂志(电子版),2019,11(1):79-82. [12] 陈亚军,罗俊,韩怡.胃蛋白酶原1、G-17、HP-IgG检测,结合胃黄色素瘤对诊断萎缩性胃炎准确性分析[J].分子诊断与治疗杂志,2021,13(4):547-550. [13] 刘宇,杜小龙,王钢.参芪消痞汤对慢性萎缩性胃炎癌前期病变患者肿瘤标志物及血清p53蛋白、MDA、GSH-Px的影响[J].中医学报,2021,36(1):182-186.
2022, Vol. 28 
冀公网安备13080202000677号